SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back

: Strategies For Diagnosis and Treatment of Adult ADHD in Primary Care
Activity/Course #:
: RealCME740016x
: Free
Release/Start Date:
: Dec 22 2016
Expiration Date:
: Dec 22 2017
: Primary Care Medicine
Target Audience:
: Primary Care Providers
: Flipped Classroom
Estimated Time To Complete CME Activity:
: 1.0 Hours
: 0
Hardware/Software Requirements:
While once thought of as a childhood disorder that primarily affected “disruptive” boys, ADHD is now known to persist into adulthood in approximately 60% of cases with an overall prevalence of 3-4% of US adults. Unlike earlier beliefs, it is now known that the nearly as many women have ADHD in adulthood with a male-female prevalence of 1.6: to 1. The condition can be detrimental to many areas of life including work, daily activities, social and family relationships and psychological and physical well-being.

Appropriate treatment of ADHD in adults can provide dramatic symptomatic improvement with some of the largest treatment effects of any medical condition.

Recognition and treatment of adult ADHD is important, especially because of the potential for dramatic symptomatic improvement. However, the condition is underdiagnosed and undertreated in practice.

This activity utilizes a flipped classroom design. This begins with a foundational self-study followed by an online live webinar, which will be available on-demand after the live event, where all participants will have the opportunity to interact with the faculty and other learners. This provides an opportunity to discuss more specific management questions and strategies of care.

Learning Objectives
After completing this activity, the reader should be better able to:

  1. Describe ADHD symptom profiles and common presentations in a primary care setting.
  2. Identify risks for coexisting disorders in adult patients with ADHD with emphasis on anxiety disorders, mood disorders, and substance use/abuse disorders.
  3. Implement appropriate pharmacologic treatment for adults diagnosed with ADHD designed to improve compliance, minimize side effects and maximize outcomes in a busy primary care setting.
  4. Use adult ADHD assessment and treatment tools for assessment, treatment and follow-up monitoring.

How To Obtain Your CME Certificate

  1. Read the learning objectives and faculty disclosures.
  2. Participate in the activity.
  3. Complete the post-test and activity evaluation.
  4. Physicians who successfully complete the post-test and evaluation will receive CME credit.
  5. Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
  6. You must score 60% or higher on the post-test to receive credit for this activity.
  7. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 hrs contact hours of continuing education (which includes 0.25 hours of pharmacology)
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure is provided below.

Gregg Mattingly, MD, Faculty, serves as a Speaker for Allergan, Lundbeck, Merck, Otsuka, Shire, Sunovion, Takeda and Vanda. Dr. Mattingly also serves as a consultant for Alkermes, Allergan, Forum, Lundbeck, Merck, Otsuka, Perdue, Rhodes, Shire, Sunovion, Takeda and Vanda. Additionally, he serves as a researcher for Akili, Alcobra, Alkermes, Allergan, Boehringer, Forum, Janssen, Medgenics, NLS-1 Pharma AG, Reckitt Benckiser, Shire, Sunovion, Supernus and Takeda.

Planning Committee
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.

Harvey Parker, PhD, has no real or apparent conflicts of interest to report.

Josh Kilbridge has no real or apparent conflicts of interest to report.
Commercial Support
This activity is supported by an educational grant from Shire.